OTC drug market to grow by more than 8%

The market for over-the-counter veterinary drugs is expected to grow at a CAGR of 8.10% during the next decade, according to a report by research analysis company, Future Market Insights. The market was valued at $8.32 billion at the beginning of the forecast period of 2022 to 2032. By the end of the period in 2032, the market was forecast to exceed a value of $18.14 billion. 

Market uptick is projected based on increased utilization of pet healthcare and treatment therapies and increased adoption of pet health insurance. Adding to the expected revenue is the increasing costs associated with such pet care and pet insurance. 

A newcomer to the prescription and OTC space in pet medications is the online pharmacy which seamlessly provides access to pet treatment regimens and supplements. The sales channel is forecast to make up 37.8% of the 2022 overall worldwide market.

Additionally, market players in OTC pet medication are continuously launching new products and engaging in business ventures that increase the reach of their brands. As a trend across the market, OTC veterinary drug makers have also recently been involved in acquisitions and partnerships as a method to increase footprint. 

By geography, the North American segment in the worldwide OTC veterinary drug market was expected to garner a leading share in 2022, estimated at 34.7%. The largest segment by product form is expected to be oral medications with more than 75% of global share, and CAGR increase of 7.9% across the forecast period. 

By class of drug segment, the anti-parasitic medication segment was expected to grow at a CAGR of 8.10% and to make up 12.8% share the global market. 

  • Please enter a comment

Name *
Email address *
Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

More news

Cattle Market Forecast 2024


Mechanical osteoarthritis of the hip in a one medicine concept: a narrative review


Placebo-Controlled Trial of Daily Oral Cannabidiol as Adjunctive Treatment for Cats with Chronic Gingivostomatitis


Comparison of metrics to assess antibiotic use in small ruminants at a university referral clinic between 2005 and 2019 


Retrospective evaluation of the incidence of gastrointestinal bleeding in dogs receiving ophthalmic nonsteroidal anti-inflammatory drugs




News of interest


Copyright © 2023 - All Rights Reserved
ISSN 2768-198X